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Abstract 
 In the future, it may be possible to slow the change in cognition associated with 
menopause. First, we must understand the mechanism with which different biological processes 
interact in order to slow this decline at the source. An important gene that plays a role in 
cognition and aging is the gene for catechol-o-methyltransferase, which is an enzyme that 
degrades dopamine in the prefrontal cortex (PFC). Different genotypes cause expression of 
varying amounts of the enzyme intended to degrade dopamine in the synapse. When estrogen is 
present in the system, transcription of COMT is inhibited. The cognitive effect of the interaction 
between lifetime estrogen exposure and COMT was examined in 65 healthy postmenopausal 
women. In this study, we tested episodic and working memory, which are associated with PFC 
functioning. The subjects were genotyped for the COMT SNP (single nucleotide polymorphism). 
An index of lifetime estrogen exposure (ILEE) was created that incorporated reproductive period 
(menarche to menopause), total duration of breast-feeding, total time on hormonal therapy, and 
time since menopause. We found that in working memory and episodic memory measures, the 
effects of ILEE on cognition depended on the COMT genotype. This study showed that 
cognition in women with the lower dopaminergic baseline gene, Val/Val, benefitted from 
lifetime estrogen exposure. However, cognition in women with the higher baseline dopamine 
gene, Met/Met, was negatively affected by lifetime estrogen. Women with the Met/Val gene 
were not as impacted by lifetime estrogen. These results suggest that the COMT gene should be 
taken into account when considering exogenous estrogen to modulate the decline of cognition 
after menopause. 
 
Keywords: estrogen, menopause, COMT, prefrontal cortex, dopamine, cognition 
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Introduction 
Menopause may be the most important biochemical change in a woman’s life. During 
this period the noticeable effects on the brain vary greatly. Some women experience a decline in 
memory and other cognitive measures, while others experience very little pathological change. 
With the onset of menopause, cognitive decline may be accelerated (Halbreich et al., 1995a). 
This acceleration might be due to a deficiency of gonadal hormones, including estrogen. It is 
important to understand the underlying neurobiological and genetic mechanisms of menopause 
and aging.  
Aging causes a decrease in the availability of dopaminergic receptors in the brain, shown 
using positron emission tomography (Volkow et al., 1998; Wong et al., 1984). Dopamine is a 
neurotransmitter that is involved in cognition and the functioning of the dopaminergic system 
changes in normal aging (Braver and Barch, 2002).  Dopamine is synthesized in the substantia 
nigra and the ventral tegmental regions (VTR) of the brain. From the VTR, it follows the 
mesocortical pathway to affect cognitive processes, circulating through the striatum and to the 
prefrontal cortex (Malenka et al., 2009).  
The concentration of dopamine in the prefrontal cortex (PFC) is controlled by the COMT 
gene, which encodes for the COMT enzyme (Lachman et al., 1996). Although the primary site of 
the COMT enzymatic interaction with dopamine occurs in the PFC, this enzyme is widely 
expressed throughout the brain. The region where the highest dopamine or dopamine metabolite 
concentration is the basal ganglia, specifically the lateral putamen, along with high levels found 
in the caudate nucleus and the nucleus accumbens (Hall et al., 1994). In regions like these, the 
dopamine transporter (DAT) is more likely to control dopamine concentrations since the DAT 
has a thousand times greater dopamine affinity then the COMT enzyme (Lewis et al., 2001). 
ESTROGEN AND COMT IN POSTMENOPAUSAL WOMEN                                         4 
 
However, PFC dopamine levels are unaffected by DAT since the DAT is minimally expressed in 
this area (Huotari et al., 2002; Sesack et al., 1998). This means the COMT enzyme is the primary 
mediator of dopaminergic functioning in the PFC. In addition, mice COMT knockout studies 
suggest that dopamine concentration was substantially greater in the PFC compared to the 
striatum, where the dopamine transporter mainly controls dopamine functioning (Gogos et al., 
1998). Further research shows that COMT mRNA levels are greater in the PFC than the striatum 
(Matsumoto et al., 2003). Therefore, COMT primarily mediates prefrontal cortex dopamine 
levels rather than other brain areas, suggesting that COMT controls PFC derived cognitive 
processes, including working memory.  
This COMT gene has a SNP, which determines COMT enzymatic activity, with the Met 
allele having about a quarter of the dopamine degrading enzymatic activity of the Val allele 
(Chen et al., 2004). Dopamine impacts cognitive functioning related to the PFC, which includes 
working memory, attentional control, and episodic memory (Egan et al., 2001; Schott et al., 
2006). Cognition is impacted differently when different concentrations of dopamine are present. 
Specifically, the dopamine receptor produces an inverted-U dose-response, with too little or too 
much dopamine impairing working memory (Vijayraghavan et al., 2007). It is important to 
understand the factors that impact dopamine concentration. 
Human dopamine functioning undergoes dynamic changes through development, 
affecting the male and female brains differently (Schulz et al., 2009). In addition, an animal 
model of primates suggested that females experience a decline in working memory with the 
onset of menopause, independent of age (Hara et al., 2014). Both of these findings imply that the 
dopaminergic system is affected by sex hormones, which readily cross the blood-brain barrier. 
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Research shows that estrogen’s role in cognition is primarily mediated by the PFC and its 
circuitry (Keenan et al., 2001; Krug et al., 2006). Specifically, estrogen has a direct effect on the 
COMT gene by inhibiting transcription when estrogen is bound to both response elements on the 
promoter of the gene (Weinshilboum, 2006; Xie et al., 1999). Evidence suggests that estradiol 
increases dopamine activity (Thompson and Moss, 1994) and dopamine synthesis, release, and 
turnover (Becker, 2000). Therefore, the COMT genotype and exposure to estrogen both affect 
the amount of dopamine in the brain, which in turn impacts cognition.  
One study on premenopausal women found cognitive changes based on the interaction 
between COMT and estrogen levels during the menstrual cycle (Jacobs and D'Esposito 2011). 
Moreover, this study determined that optimal dopaminergic system functioning occurred in the 
Met/Met genotype, but the Val/Val genotype combined with high estrogen during the menstrual 
cycle showed the greatest effect on brain functioning during a working memory task. This 
finding demonstrates that the changes in hormone levels during the menstrual cycle interact with 
the COMT genotype to influence performance and brain functioning during a working memory 
task.   
Many studies examined the cognitive influence of exogenous estrogen use during or after 
menopause, each with varying results (Carlson et al., 2001; Lethaby et al., 2008; Maki, 2005; 
Ryan et al., 2009). There are several theories for these inconsistencies. One is that a “critical 
window” of estrogen exposure during menopause increases neuroprotection, and different ages 
of hormone therapy (HT) may be the reason for variation in the results. Another theory is that 
genetic components in the brain impact the range of cognitive results from HT. Lastly, lifetime 
estrogen exposure might modulate the effects of HT through menopause. In order to test the 
lifetime estrogen theory, studies have explored cognitive changes associated with lifetime 
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estrogen exposure, but these results are varied as well (Low et al., 2005; Tierney et al., 2013). 
Tierney et al. (2013) found that the reproductive period (between menarche and menopause) 
length was related to better delayed visual memory, immediate and delayed verbal memory, and 
working memory. On the other hand, Low et al. (2005) determined that the reproductive period 
length had no detectable effect on cognition. These studies had not taken into account the COMT 
genotype, which may be one reason for the varying results. No one has studied the cognitive 
effects of lifetime estrogen with the COMT genotype in postmenopausal women.  
Studies often used different markers to identify cumulative estrogen exposure. Several 
well-researched factors cause changes in estrogen levels throughout a woman’s life. Exogenous 
gonadal steroid use through hormonal contraceptives directly increases estrogen levels. The 
duration and age of use of exogenous gonadal steroids could have different effects on 
postmenopausal cognition. There are also many endogenous factors that influence hormones. 
The duration in a woman’s life when she is reproductive, marked by age at menarche and age at 
menopause, influences serum estrogen levels (Geerlings et al., 2001). Pregnancies increase short-
term estrogen levels because the placenta synthesizes and releases estrogen into the body (Siiteri 
and MacDonald, 1966).  Levels of estrogen are also influenced by interruptions in pregnancies, 
whether they are spontaneous abortions (Coulam and Stern, 1994) or induced abortions (Daling 
et al., 1996). The Body Mass Index (BMI) of an individual also increases estrogen in the body 
(Lukanova et al., 2004). The duration of breast-feeding postpones ovulation due to inhibition of 
FSH stimulation in the ovary, and has been shown to depress plasma estrogen levels (Bonnar et 
al., 1975).  
 Rather than examining these lifetime estrogen factors individually, it has been shown that 
combining multiple markers into one index increases analytical power and makes results more 
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apparent (Smith et al., 1999). Smith et al. (1999) combined several estrogen markers into a 
simple Index of Estrogen Exposure (IEE). Factors with clear effects on estrogen were used in 
this index. The IEE excluded most reproduction factors because although pregnancy 
considerably increases short-term estrogen levels, the long-term implications are more 
complicated. Research suggests that parous women experience a gradual decrease in estradiol 
level with age during the follicular phase until menopause (Dorgan et al., 1995). Conversely, 
follicular phase estradiol levels increase with age in nulliparous women prior to menopause. To 
construct the IEE, Smith et al. (1999) standardized the data, then added time on postmenopausal 
estrogen therapy, age at menopause, nulliparity, and postmenopausal weight. Age at menarche 
and time since menopause were subtracted. This study found that the IEE was most strongly 
correlated with global cognitive functioning and verbal attention. No individual estrogen marker 
was related to cognition. 
 Another study used the IEE based on Smith et al. (1999) but included breast-feeding as a 
factor that decreased estrogen (Hesson, 2012). They called this index the Index of Cumulative 
Estrogen Exposure (ICEE). No significant relationship was found between ICEE and 
retrospective memory, but the data suggested prospective memory was positively correlated with 
ICEE. In the current study, two indexes of estrogen exposure were used: one that measured every 
variable recorded in the questionnaire (TLEE), and another based on the research of Smith et al. 
(1999) and Hesson (2012), using only markers that clearly increased estrogen (ILEE). The main 
difference between these two created indexes is that the TLEE includes total duration pregnant 
and hormonal contraceptives, while the ILEE takes into account years since menopause onset. 
The current study examined the interaction between the lifetime estrogen exposure in 
postmenopausal women and functioning of the dopamine system in the brain. The purpose of 
ESTROGEN AND COMT IN POSTMENOPAUSAL WOMEN                                         8 
 
this study was to examine how lifetime estrogen exposure interacted with the COMT gene to 
affect cognition after menopause, which no other study has examined. Depending on how the 
cognitive performance of women with different genotypes is affected by lifetime estrogen, there 
may be different hormonal treatments or lifestyle choices suggested in the future. It was 
hypothesized that a longer period of exposure to estrogen had a greater effect on cognition in 
women with lower dopaminergic functioning, the Val/Val genotype of COMT, more than 




Women were recruited by calling past research subjects of the Clinical Neuroscience 
Research Unit (CNRU) in the Department of Psychiatry and by posting advertisements around 
the community. These participants were recruited from the community, and the sample was not 
biased based on estrogen use. Once a potential participant called or answered the phone, these 
women were told about the study, and then answered questions about medical history during a 
telephone screening. Inclusion criteria were an age of 60 to 70, postmenopausal, and healthy. 
Women were excluded if they were current smokers, currently taking any medications that 
affected the central nervous system, such as anti-depressants, anti-anxiety medications, 
antihistamines, or medications altering the dopamine system. Medical history exclusions 
included diabetes, heart disease, cancer, chronic obstructive pulmonary disease, depression, 
anxiety, and a medical history of loss of consciousness for more than ten minutes due to head 
trauma. If a potential participant passed an initial telephone screening regarding age, medication 
use, disease history, and menopause history she was scheduled at the University of Vermont 
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Clinical Research Center (CRC) for one three-hour study visit. Once the participant arrived, 
authorization and consent forms were signed. Each woman provided a DNA sample, completed 
cognitive and behavioral screening tests, completed a questionnaire to disclose health 
information, answered questions about lifetime estrogen exposure, performed cognitive tasks to 
examine working memory and episodic memory, and filled out a series of questionnaires about 
subjective cognitive complaints. Details about each of these procedures are below 
Cognitive Impairment Screening Tests 
All subjects completed a set of initial cognitive status screening questionnaires: Mini 
Mental State Exam (MMSE) (Folstein et al., 1975), Dementia Rating Scale (DRS) (Jurica et al. 
2001), and Brief Cognitive Rating Scale (BCRS) (Reisberg and Ferris, 1988) which lead to the 
Global Deterioration Score (GDS) (Reisberg et al., 1982). On both the DRS and MMSE, a higher 
score is related to better global cognitive functioning. Subjects were required to have a score 
equal to or greater than 26 on the MMSE, and a DRS score equal to or greater than 123. On the 
GDS and BCRS, a higher score was related to a greater amount of cognitive impairment. On the 
GDS, a score of 1 or 2 was required for eligibility. 
Behavioral Screening 
A series of behavioral screening questionnaires was used. This included a modified 
version of the Structured Clinical Interview for DSM-IV-TR (SCID) (First et al. 2001), which 
screened for current and past depression, current manic disorder, and current dysthymia.  In 
addition, the Beck Depression Inventory (BDI-II) screened for current depression (Beck et al. 
1996). In order to be considered depressed, a score higher than 9 on the BDI was used, along 
with an assessment of current major depressive disorder on the SCID. If a subject endorsed 
current depression on the SCID, her data were not included in analyses. None of the subjects in 
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the present study endorsed current depression, and thus were not ruled out due to the SCID. The 
Beck Anxiety Inventory (BAI) was used as a screen for anxiety (Beck et al., 1988). Subjects 
were disqualified from all analyses if a score above 15 was calculated from the BAI. One subject 
scored greater than 15 and her data were removed from the analysis. We used the Menopause 
Symptom Checklist to review the severity of menopausal symptoms the subjects experienced in 
the past month. This questionnaire was created by Newhouse and Sargent (2002), modeled after 
the Sherwin Menopause Index (Sherwin, 1991). Another questionnaire used for behavioral 
screening was the Pittsburg Quality Sleep Index (PQSI), which determined quality of sleep in the 
past month (Buysse et al., 1989).  
Subjective Cognitive Complaints 
Each woman filled out a series of questionnaires used to determine subjective cognitive 
complaints of subjects, the Cognitive Complaint Index (CCI). This battery included Memory 
Assessment Questionnaire (Pfeffer et al., 1982), Memory-Self Rating Questionnaire (Squire et 
al., 1979), Informant questionnaire on cognitive decline in the elderly (Jorm et al., 1994), and ten 
questions about mild cognitive impairment (Rabin et al., 2007). More subjective cognitive 
complaints had shown to be related to increased neurodegeneration (Saykin et al., 2006). These 
subjective cognitive complaints were not related to objective cognitive complaints, but were still 
related to brain functioning. 
Cognitive Tasks 
Working Memory – N-back Test 
The N-back Test was used as a measure of verbal working memory. In this task, the 
subject viewed a string of consonant letters (except L, W, and Y), one every 3 seconds. Four 
conditions were presented: 0-back, 1-back, 2-back and 3-back. In each of the 1-back, 2-back, and 
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3-back conditions, the task was to decide whether the letter currently presented matched the 
letter that has been presented 1, 2, or 3-back in the sequence. The subjects were asked to press 
the “match” button when the letter on the screen matched the letter for the certain conditions, and 
the “mismatch” button for every other letter. In the 0-back condition, the subject was given a 
target letter and she made a “match” response when that target appeared. This condition required 
attention and focus, but no working memory. In the one-back condition, the goal was to press the 
match button when a letter matched the letter that appeared just prior (the letter appearing one 
item back).  In the two-back condition, the match occurred when a letter was identical to the 
letter two items back. In the three-back condition, a match occurred when a letter was identical to 
the letter that appeared three items back. Participants were given two trial rounds of each 
condition before performing the full N-back task used in this study. Accuracy measures and 
reaction times were automatically recorded for each trial. Dumas et al. (2010) have shown that 
estrogen in postmenopausal women affected prefrontal brain regions involved in this task. 
Episodic Memory Buschke Selective Reminding Test (SRT) 
The Buschke SRT was used to measure episodic memory (Buschke and Fuld, 1974). The 
SRT is a multi-trial verbal list-learning task allowing the examination of acquisition, encoding, 
and retrieval. This standard test offers measures of storage into and retrieval from memory. For this 
task, a list of 16 unrelated words was read aloud to the subject. The subject recalled as many words 
as possible. Then, the person administering the task would selectively remind the subject of the 
words that she did not recall, and asked her to try to recall the list of 16 words again. There were 
eight trials in this task. In addition, there was one trail that was administered about 20 to 30 minutes 
after the end of the eighth trial. The total recall was the total amount of words the subject recalled 
from all eight trials. Consistency occurred when the subject remembered a word in succession for 
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two trials. Intrusions were words the subject recalled not on the specified list. Recall failure 
occurred when the subject failed to remember a word on two consecutive trials. Totals among these 
variables in all trials were added to give total recall, total consistency, total recall failure, total 
intrusions, and delayed recall. 
Indices of Estrogen Exposure Questionnaire 
Each woman answered questions about lifetime hormone exposure divided into 4 
sections: menstrual cycle history, motherhood, menopause, and history of HT (Lord et al., 2009).  
The menstrual cycle history inquired about age at menarche, amenorrhea, and contraceptive 
hormone use. The motherhood section asked about pregnancies, miscarriages, and breast-
feeding. The next section included age at menopause and whether it was natural or surgically 
induced. The last section was about hormonal therapy type, duration, and age. Lord et al. (2009) 
found this self-report estrogen use questionnaire to be reliable. The data collected from the 
questionnaire was converted into hormone history indices.  
Index of Lifetime Exposure to Estrogen (ILEE) 
All estrogen exposure markers were converted to years. Duration of breast-feeding was 
added across children for each woman, resulting in the total duration of breast-feeding. Time 
since menopause was calculated as current age minus age at menopause (age at last period). 
Adding all durations of hormonal therapy used for menopause created total hormonal therapy 
(total HT). To form the index, factors causing an increase in estrogen were added (age at 
menopause, total HT), and the markers that lead to a decrease in estrogen were subtracted (time 
since menopause, age at menarche, and total duration of breast-feeding). This index was based 
off of Smith et al. (1999) and Hesson (2012). However, unlike their models, I did not include 
postmenopausal weight (Smith) or BMI (Hesson) because this factor was an instantaneous 
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measurement rather than constant throughout life. I also did not include nulliparity in this index 
because the short-term and long-term effects of pregnancy on estrogen levels have shown to be 
contrasting (Dorgan et al., 1995). 
Total Lifetime Estrogen Exposure (TLEE) 
TLEE was an index that included all the variables on the questionnaire. Pregnancies were 
converted to years, and then added into the total duration pregnancy for each woman. Hormonal 
contraceptives were converted to years, creating the total hormonal contraceptives measure. The 
markers that cause an increase in estrogen were added (total duration pregnancy, total duration 
hormonal contraceptive, total duration hormonal replacement therapy, reproductive period from 
menarche to menopause) and one factor that is related to low estrogen (duration of breast-
feeding). 
Genotype 
Subjects provided a buccal DNA sample. A clinical research nurse from the University of 
Vermont Medical Center, specifically the Clinical Research Center (CRC), ran a buccal cheek 
swab across the inside of each woman’s cheek. Then, the sample was stored in a -20°F freezer 
until all the samples were collected. DNA extraction and single nucleotide polymorphism (SNP) 
analysis were conducted at the Vermont Cancer Center DNA Analysis lab. COMT val158met 
polymorphism was determined using TaqmanTM Genotyping Master Mix. The PCR products 
were analyzed using Applied Biosystems Prism 7900HT Sequence Detection System, version 
SDS 2.4. Each woman was either Met/Met if there were two adenosine nucleotides at this loci, 
Met/Val if both alleles were present, or Val/Val if there were only guanine nucleotides.  
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Vital Signs and BMI 
During each study day, a clinical research nurse from the CRC obtained height, weight, 
and the vital signs: respiratory rate, blood pressure, temperature, and pulse rate from the subject. 
Based on the height and weight, we calculated BMI for each subject. 
Data Analysis 
The COMT genotype was used as a grouping variable. In addition, a median split was 
used to separate women into high and low estrogen groups based on ILEE and TLEE separately. 
To test my hypotheses about lifetime estrogen exposure, COMT genotype, and cognition after 
menopause, I used a 2(ILEE: high and low) x 3(COMT genotype: Val/Val, Met/Val, Met/Met) 
ANOVA. ILEE group and genotype were between subjects factors. The ILEE hormone exposure 
variable was also used a continuous variable, changing the analyses into a regression model. 
Since the indices I used have many variable components, I also explored the correlations 
between cognition and the different markers for estrogen exposure individually. Many studies 




A total of 67 subjects were enrolled. Two subjects were excluded from analyses. One was 
ineligible because she was unable to finish the study day due to mental fatigue. The other 
reported above the allotted BAI score for anxiety. Out of the 65 analyzed subjects, 19 were 
Val/Val, 36 were Val/Met, and 10 were Met/Met. Table 1 shows the means of age, education, 
and BMI for the different genotypes. 
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Subjects ranged from 60 to 70 years old, with a mean age of 64.3 years (SD 3.1). These 
women had a mean education of 16.6 years (SD 1.9) and a mean BMI of 26.9 (SD 5.7). The 
average age at menarche was 12.7 years (SD 1.3) and the average age at menopause was 52.1 
years (SD 3.3). In this study, 72.3% of women were parous, and, including pregnancy 
interruptions, like abortions and miscarriages, the mean total duration of pregnancy was 1.6 years 
(SD 1.1). Out of all the women analyzed, 61.5% breast-fed at least one child. 83.1% of the 
women reported using hormonal contraceptives, and the mean total duration of birth control for 
all women was 5.43 years (SD 6.4). In addition, 44.6% of the women used postmenopausal 
hormonal therapy throughout menopause, and among those, the mean duration of HT was 4.7 
years (SD 5.1). Table 2 shows the averages for the estrogen markers measured. The means of the 
screening tests (Table 3), behavioral data (Table 4), and cognitive tasks (Table 5) are reported. 
Working Memory (N-Back) 
2-Back Hits, ILEE Grouping Variable, and COMT Genotype 
The 2-Back condition measures working memory. In this condition, women were asked 
to indicate if the current letter matched the letter that appeared two items before.  
 There was an interaction between COMT genotype and the ILEE groups for the 2-back 
condition of the N-back working memory task (F(2,59)=3.80, p=0.028). There was also a main 
effect of COMT genotype (F(2,59)=3.66, p=.032). There was no main effect of the ILEE 
grouping variable (p=.23) (Table 6). Overall, the means showed the Val/Val group performed 
better than the Met/Val and the Met/Met groups. The post hoc t-test showed there was no 
significant difference between the Val/Val and the Met/Val groups (t(53)=1.97, p= 0.054) or 
between the Val/Val and Met/Met groups (t(27)=1.52, p=0.140). For the Val/Val group, the 
means showed that women in the low ILEE group performed worse than the women in the 
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Val/Val who were in the high estrogen ILEE group, but the post hoc t-tests were not significant 
(t(17)=1.53, p=.143). For the Met/Val group there was no difference between the high and low 
ILEE group (t(34)=0.197, p=.845). For the Met/Met group, there was a significant difference 
between the high and low ILEE group, with the low estrogen group performing better than the 
high estrogen (t(8)=2.64, p=.030). However, there were only two women in the high estrogen 
condition (see Table 7 and Figure 1). 
3-Back Hits, ILEE Grouping Variable, and COMT Genotype 
 The 3-back condition is a more difficult task than the 2-back, as it requires holding more 
information in working memory.   
 There was no COMT genotype and ILEE group interaction for the 3-back condition 
(p=.326). However, there was a main effect of ILEE group (F(2,59)=4.93, p=0.030) and a main 
effect of COMT genotype for the 3-back of the N-back working memory test (F(2,59)=4.00, 
p=0.024) (Table 6).  Overall the Met/Met group performed worse than the Met/Val (t(44)=2.06, 
p=.045) . The means showed that the Met/Met performed better than the Val/Val, but not 
significantly (t(27)=1.56, p=.130). There was no significant difference between the Met/Val and 
Val/Val groups (t(53)=0.084, p=.934).  The means display the low estrogen performed better 
than the high estrogen group. There were no significant differences between high and low 
estrogen groups (t(63)=1.34, p=.186) (see Table 8 and Figure 2). 
Episodic memory (SRT) 
Total Recall, ILEE Grouping Variable and COMT Genotype 
There was an interaction between COMT genotype and the ILEE groups for the total 
recall condition of the Buschke SRT for episodic memory (F(2,59)=3.67, p=0.03). There were 
no main effects of the COMT genotype (p=0.12) or the ILEE groups (p=0.82) (Table 6). For the 
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Val/Val women, the low ILEE group performed worse than the high ILEE group, but not 
significantly (t(17)=1.85, p=0.081). For the Val/Met women, high and low estrogen group 
performance did not differ much (t(34)=0.270, p=0.789). For the Met/Met group, the means 
indicated that low estrogen exposure group performed better than the high estrogen group, but 
not significantly (t(8)=2.088, p=0.070). (See Table 9 and Figure 3). 
SRT Total Recall Failure, ILEE Grouping Variable, and COMT Genotype 
There was an interaction between COMT genotype and the ILEE for the total recall 
failure condition of the Buschke SRT for episodic memory (F(2,59)=7.22, p=0.002). There were 
no main effects of the COMT genotype (p=0.13) or the ILEE groups (p=0.42) (Table 6). For the 
Val/Val women, the means showed that the low ILEE group had significantly more recall 
failures, denoting worse performance, than the high ILEE group (t(17)=2.26, p=0.037). For the 
Val/Met women, the high estrogen group and the low estrogen group had similar performance 
(t(34)=0.666, p=0.510). For the Met/Met group, the high estrogen exposure group had 
significantly more recall failures than the low estrogen group (t(8)=4.40, p=0.002) (see Table 10 
and Figure 4). 
Individual estrogen components correlate with cognition 
When I used the ILEE as a continuous variable instead of grouping variable there was no 
correlation between estrogen exposure and working memory, episodic memory, or cognitive 
complaints. However, there was a correlation between global cognitive functioning measured 
with the DRS and continuous ILEE (r= .330, p=.007). Higher global cognitive functioning was 
related to greater lifetime estrogen exposure.  
The ILEE factor has many components. Separately, some of these markers were related 
to cognition. Understanding which factors were related to cognition alone is very important and 
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many studies research individual components rather than making indices. Thus, I examined 
correlations between the individual hormone measures and the cognitive measures. 
Global Cognitive Functioning 
There was a correlation between global cognitive functioning measured with the DRS 
and the amount of time since menopause (r= -.368, p= .003). This means that less time since 
menopause was related to higher global cognitive functioning.
 
Subjective Cognitive Complaints 
There was a correlation between the subjective cognitive complaints reported with the 
MFQ and the total duration pregnant (r=.416, p=.001). Thus, greater subjective cognitive 
complaints were related to a longer total duration pregnant. 
Episodic Memory 
There was a correlation between number of total intrusions, a measure of inaccurate 
recall, on the Buschke SRT and the total pregnancy duration (r=.357, p=.004). Therefore, more 
intrusions were related to longer total duration pregnant.  
Age was an important factor among some variables of the Buschke test. Age was 
correlated with the Buschke task total recall (r= -.272, p=.029). This means that increased age 
was related to performing worse on the total recall on the Buschke SRT. Also, age was correlated 
to total consistency on the Buschke SRT (r= -.276, p= .026). Increasing age was related to worse 
performance on consistency of the Buschke SRT. Following this pattern, total recall failure on 
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Working Memory 
On the N-back task, 0-back hits were positively correlated with total menopausal 
hormone therapy duration (r=.286, p=021). This means that a longer duration of hormone 
therapy through menopause was related to better performance on the 0-back task. However, 0-
back hits were negatively correlated with the duration of hormonal contraceptive earlier in life 
(r= -.321, p=.009). Therefore, the longer the duration of hormonal contraceptives was related to a 
worse 0-back performance.  
For the 1-back condition on the N-back task, hits were negatively correlated with TLEE 
(r= -.29, p=.02). Higher total estrogen exposure, considering all the markers, was related to poor 
performance on the 1-back condition.  
However, performance was close to ceiling for the 0-back and 1-back conditions.  
 
Discussion 
As hypothesized, the effects of lifetime estrogen exposure on cognition were modulated 
by COMT genotype, since a greater amount of lifetime estrogen exposure benefitted the lower 
baseline dopamine genotype (Val/Val), but was detrimental to women with the higher baseline 
dopamine gene (Met/Met). Overall, the means for working memory, as measured by 2-back hits, 
and the episodic memory measures, SRT total recall and SRT recall failure, suggested that the 
effects of ILEE on cognition depended on the COMT genotype. This study showed that 
cognition in Val/Val women was positively affected by lifetime estrogen exposure. However, 
cognition in women with the higher baseline dopamine gene, Met/Met, was more negatively 
affected by higher lifetime estrogen exposure. Women with the Met/Val gene displayed 
cognitive performance that seemed unaffected by lifetime estrogen. This is probably because in 
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the PFC, dopamine was most beneficial at an intermediate concentration, but more detrimental as 
it reached the extremes. 
Interactions between genotype and estrogen affecting cognition were also found in an 
fMRI study of premenopausal women (Jacobs and D'Esposito, 2011). In the Jacobs and 
D'Esposito (2011) study, the effects of estrogen depended on the baseline of dopamine 
determined by genetics. The fMRI showed similar results to my study because Jacobs and 
D'Esposito found Met/Met women performed best under low estrogen conditions and decreased 
performance under high estrogen conditions. In addition, the Val/Val subjects had impaired 
cognition when estrogen was low, but improved performance with higher estrogen. 
With the increased working memory load in the 3-back condition, the interaction of 
COMT and ILEE group on cognition no longer occurred. However, main effects of both 
genotype and ILEE were present. The ILEE main effect for the 3-back condition had means that 
displayed the low ILEE group performed better than the high ILEE group. The genotype main 
effect showed the Met/Met genotype did worse than both the Val/Val and the Val/Met. In 
addition, the greatest performance difference between high and low ILEE occurred in the 
Met/Met genotype, with the high ILEE Met/Met group performing worse than all other groups. 
When considering the main effects of ILEE and genotype separately, it appeared the women with 
higher dopamine performed worse. This might be because studies have suggested more 
dopamine correlated with increased anxiety, which is related to a decreased attention control that 
may have affected performance on the difficult 3-back condition (Eysenck et al., 2007). In 
addition, research suggested that anxiety is a characteristic of the high baseline dopamine allele, 
Met/Met (Olsson et al., 2005). An fMRI study suggested that due to the difficulty level, the 3-
back condition caused more disengagement, and the 2-back was likely a better predictor of 
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working memory because most subjects can remain focused and with continual effort (Ayaz et 
al., 2012). This disengagement is likely seen in higher dopamine individuals more because of 
higher anxiety rates. Therefore, the 3-back condition might not be as predictive of cognitive 
performance as the 2-back condition. 
 In addition to the results of the results from the ANOVA, there was a correlation between 
ILEE as a continuous variable and global cognitive functioning. This is a replication of the 
finding by Smith et al. (1999), suggesting that increased global cognitive functioning is related to 
women with greater lifetime estrogen exposure. However, ILEE as a continuous variable was not 
correlated to working memory or episodic memory. When grouped by a median split into high 
and low ILEE, there were effects on working memory and episodic memory. Further research is 
necessary in order to understand these relationships. 
Limitations 
One limitation in this study is that the Met/Met high estrogen group had a sample size of 
two women. Both of these women performed similarly in episodic memory and working memory 
tasks so there was at least no outlier in their performance. However, the relationship between 
cognition, estrogen, and COMT genotype found in this small sample size may be unreliable. A 
larger sample size of Met/Met women is needed to confirm that these results are not due to 
chance. The total sample size is a limitation to this study. With a larger sample, statistical power 
would be greater. Additionally, the women in this study were well educated, Caucasian, and all 
from the Vermont area. This sample probably does not accurately represent the population of 
postmenopausal women. With a larger sample size and greater variance through the sample, our 
results would be more reliable. 
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A second limitation was that the estrogen questionnaire was retrospective. The data were 
collected solely by subjective memory, and thus may not represent the true levels of lifetime 
estrogen exposure. However, prior studies have shown that the duration of hormone therapy 
through menopause and type of menopause (surgery, natural) were highly correlated with 
medical record findings of these events (Colditz et al., 1987; MacLennan et al., 2006). Other 
factors were found to be reliable, but not necessarily accurate in retrospective events because not 
compared to medical records. These included age at menarche, number of pregnancies, duration 
of hormonal contraceptive, and duration of HT use (Lord et al., 2009). In addition, doses of 
hormonal contraception and HT were not included since these factors were often unable to be 
reported. In addition, diet and lifetime BMI may be important factors when considering lifetime 
estrogen exposure, but since this study is retrospective, this information may be inaccurate or 
unreliable. Collecting data from both the women and medical records would reduce the chance 
of inaccuracies in the estrogen exposure data.  
Future Directions 
This study examined working memory, which has primarily function of the frontal lobes 
(Goldman-Rakic et al., 2004; Kane and Engle, 2002), and episodic memory, which is primarily a 
function of the hippocampus (Burgess et al., 2002). The N-back task has been shown in fMRI 
studies to reliably activate the bilateral frontal lobes but also activates bilateral parietal lobes and 
bilateral cerebellum (Cohen et al., 1997). The Buschke is a measure of episodic memory, which 
primarily requires hippocampal functioning for good performance (Buschke and Fuld, 1974; 
Rosen et al., 2003). However, the frontal lobes are also involved in episodic memory 
performance (Wheeler et al., 1995). A future study might attempt to use cognitive tasks that 
require smaller or more prescribed brain networks for their performance. However, the current 
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tasks were chosen because of the reliable nature of the brain networks that they require for good 
performance.  Some potential examples might be a test of spatial navigation to specifically 
involve the hippocampus or a category test or decision-making tasks (Shepard et al., 1961) to 
examine frontal lobe function further.   
Conclusions 
Many studies show that lifetime estrogen exposure increased cognition later in life (Heys 
et al., 2011; Li et al., 2014; Ryan et al., 2009; Silverman et al., 2011), although results varied 
(Low et al., 2005). Studies reported that estrogen modulates cognition by inducing dendritic 
spine formation of the CA1 region of the hippocampus in a temporary fashion (Woolley and 
McEwen, 1992). However, this finding does not support why lifetime estrogen would impact 
cognition in the PFC. One study explored the effects of estradiol on the PFC in female monkeys 
and suggested that that long term exposure to estradiol (17β) with cyclical peaks may be the most 
effective way to cause dendritic spine generation, turnover, and consolidation (Hao et al., 2006). 
Therefore, it is possible that lifetime estrogen, particularly the reproductive period from 
menarche to menopause, induces a permanent change in dendritic spines. 
There are a number of potential mechanisms that may explain how lifetime estrogen 
affects cognition after menopause. Estrogen influences multiple neurotransmitters, including 
cholinergic (Bora et al., 2005; Luine, 1985), serotonergic (Halbreich et al., 1995b), adrenergic 
(Sar and Stumpf, 1981), and dopaminergic (Roy et al., 1990) systems. In addition, estrogen 
affects the brain in a number of ways.  Estrogen is an endocrine sex hormone produced in the 
ovaries, which also functions in the central nervous system. Research has shown that estrogen 
can also be locally synthesized in the brain from cholesterol and act in as a paracrine hormone 
(Do Rego et al., 2009). This locally synthesized estrogen can regulate synaptic plasticity (Kretz 
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et al., 2004), as well as neurogenesis in the dentate gyrus (Tanapat et al., 2005). Estrogen can 
also be produced by neurons or astrocytes, or from circulating testosterone by aromatase. The 
aromatase level in the PFC was found to be significantly higher in females than males (Wei et 
al., 2014). Research shows that inhibited aromatase is related to memory impairment in females 
(Phillips et al., 2011). In an animal model, the brain-derived estrogen was a more direct and 
significant risk factor for cognitive decline by Aβ plaque formation than circulating estrogen 
(Yue et al., 2005). Therefore, more research is needed to determine the multiple effects of 
estrogen in the brain and how these are changed after menopause.  
Another hypothesis of circulating estrogen is that telomerase plays a role in the 
endocrine-related cognitive decline. Longer telomeres are related to lower rates of cognitive 
decline and lower rates of cardiovascular disease (Miller et al., 2003). Estrogen can reduce 
oxidative stress and inflammation (Xing et al., 2009), which may cause a quicker decrease of 
telomere length (Correia-Melo et al., 2014; von Zglinicki, 2002). Overall, it has been shown that 
endogenous estrogen exposure, measured as reproductive years, protects against telomere 
shortening, and associated with higher cognition in older women (Lin et al., 2011). 
Another possible mechanism by which lifetime estrogen impacts cognition after 
menopause is potentially by increasing cognitive reserve. Cognitive reserve is the idea that 
across the lifespan, higher education, participation in social or mentally stimulating activities, 
and complexity of occupation increases resistance to dementia (Harrison et al., 2015). Some 
studies show that women with higher levels of estrogen have better cognition (Sherwin, 1997). 
Perhaps compared to women with low levels of lifetime estrogen, women with higher lifetime 
estrogen continually displayed a better cognition, building better cognitive functioning leading 
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into older age.  However, the neurobiological mechanisms underlying cognitive reserve remain 
to be determined.  
The results of the current study suggest that women with a specific genotype would 
benefit more from estrogen therapy during menopause than others. In the future it may be 
possible to use a different form of medications to alleviate cognitive decline, such as a COMT 
inhibitor for Val/Val women. This may be more advantageous because higher levels of estrogen 
are related to an elevated risk of breast cancer (Colditz et al., 1993). In addition, some women 
have risk factors that are complications for exogenous estrogen due to medical contraindications 
or family history (Shifren and Schiff, 2010). More research with larger sample sizes about the 
interaction of lifetime estrogen, cognition, and genotype is needed before any treatment 
recommendations are made. However, the current data are a first step towards understanding 
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Demographic data Means (standard deviation) by genotype 
Genotype Age Education BMI N 
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Val/Val 64.4 (3.4) 17.3 (2.0) 24.7 (3.3) 19 
Val/Met 64.2 (3.1) 16.3 (1.6) 27.7 (6.5) 36 
Met/Met 64.1 (3.0) 16.2 (2.6) 28.6 (5.7) 10 




















Demographic and Lifetime Hormonal Exposure Means and 
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Standard Deviation 
Estrogen Marker Mean SD 
ILEE 30.1 6.9 
TLEE 49.3 7.2 
Age Menarche 12.7 1.2 
Horm. Contraceptive Duration 5.4 6.4 
Pregnancy Duration 1.6 1.1 
Breast-Feeding Total Duration .88 0.94 
Age at Menonopause 52.1 3.2 
HT Duration 2.0 4.0 
Years Since Menopause 12.1 4.6 
Note. ILEE=Index of Lifetime Estrogen Exposure; TLEE=Total 











Screening Questionnaire Means and Standard Deviation 
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Form Mean SD 
MMSE 28.7 1.1 
DRS 141 2.5 
SCID- Past 0.2 0.4 
BCRS 8.5 0.8 


















Behavioral Data Means and Standard Deviation 
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Form Mean SD 
BDI 1.3 2.1 
BAI 2.6 3.1 
Study Symptom 13.4 12.5 



















Cognitive Tasks/Complaints Mean and Standard Deviation 
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Measure Mean SD 
SRT Total Recall 82.2 13.8 
SRT Total Consistency 46.8 18.4 
SRT Total Recall Failure 11.7 8.4 
SRT Total Intrusion 1.5 2.2 
SRT Delayed Recall 10.4 3.4 
0 Back Hits 0.991 0.027 
0-Back FA 0.002 0.007 
1-Back Hits 0.93 0.134 
1-Back FA 0.022 0.041 
2-Back Hits 0.876 0.125 
2-Back FA 0.102 0.063 
3-Back Hits 0.731 0.155 
3-Back FA 0.079 0.063 









    Results of Univariate Analyses of COMT genotype, ILEE, and the interaction between 
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COMT genotype and ILEE on working memory and episodic memory. 
Dependent Variable Source DF F Sig. 
     2-Back Hits Geno 2 3.66* 0.03 
 
ILEE 1 1.45 0.23 
 
Geno*ILEE 2 3.80* 0.03 
     3-Back Hits Geno 2 4.00* 0.02 
 
ILEE 1 4.93* 0.03 
 
Geno*ILEE 2 1.14 0.33 
     SRT Total Recall Geno 2 2.23 0.12 
 
ILEE 1 0.05 0.82 
 
Geno*ILEE 2 3.67* 0.03 
     SRT Total Recall Failure Geno 2 2.11 0.13 
 
ILEE 1 0.67 0.42 
 
Geno*ILEE 2 7.22** 0.002 





 Proportion 2-Back Hits Correct Split by COMT Genotype and ILEE Group 
Geno ILEE Mean  SD N 
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Val/Val Low 0.881 0.156 9 
 
High 0.964 0.069 10 
 
Total 0.925 0.123 19 
Met/Val Low 0.862 0.128 15 
 
High 0.854 0.118 21 
 
Total 0.857 0.121 36 
Met/Met Low 0.893 0.108 8 
 
High 0.679 0.051 2 
 
Total 0.850 0.132 10 
Total  Low 0.875 0.128 32 
 
High 0.877 0.124 33 










    
 Proportion 3-Back Hits Correct and Standard Deviation Split by COMT 
Genotype and ILEE Group 
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Geno ILEE Mean  SD N 
Val/Val Low 0.754 0.160 9 
 
High 0.736 0.196 10 
 
Total 0.744 0.175 19 
Met/Val Low 0.795 0.132 15 
 
High 0.714 0.141 21 
 
Total 0.748 0.141 36 
Met/Met Low 0.688 0.114 8 
 
High 0.464 0.152 2 
 
Total 0.643 0.147 10 
Total  Low 0.757 0.139 32 
 
High 0.706 0.167 33 









    
SRT Total Recall Means and Standard Deviation Split by Genotype and Estrogen 
Group 
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Geno ILEE Mean  SD N 
Val/Val Low 70.7 19.8 9 
 
High 84.5 12.3 10 
 
Total 77.9 17.3 19 
Met/Val Low 84.0 7.1 15 
 
High 85.1 14.5 21 
 
Total 84.6 11.8 36 
Met/Met Low 85.4 11.6 8 
 
High 67.5 2.1 2 
 
Total 81.8 12.7 10 
Total  Low 80.6 13.9 32 
 
High 83.8 13.8 33 










    
SRT Total Recall Failure Means and Standard Deviation Split by Genotype and 
Estrogen Group 
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Geno ILEE Mean  SD N 
Val/Val Low 19.0 13.3 9 
 
High 8.8 5.0 10 
 
Total 13.6 10.9 19 
Met/Val Low 9.7 5.6 15 
 
High 11.3 8.0 21 
 
Total 10.7 7.1 36 
Met/Met Low 8.8 4.5 8 
 
High 23.5 0.7 2 
 
Total 11.7 7.4 10 
Total  Low 12.1 9.2 32 
 
High 11.3 7.6 33 
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Figure 1. Mean proportion correct and standard error of 2-Back Hits split by genotype and Index 
of Estrogen Exposure (ILEE) group. There was an interaction between COMT genotype and the 
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ILEE groups for this task (F(2,59)=3.80, p=0.028). There was also a main effect of COMT 
genotype (F(2,59)=3.66, p=.032). For the Met/Met group, there was a significant difference 
between the high and low estrogen group with the low ILEE group performing better than the 
high ILEE group (t(8)=2.64, p=.030).  *p< 0.05. 
Figure 2. Mean proportion correct and standard error of 3-Back Hits Split by Genotype and 
Index of Estrogen Exposure (ILEE) group. There was a main effect of ILEE group 
(F(2,59)=4.93, p=0.030) and a main effect of COMT genotype for the 3-back of the N-back 
working memory test (F(2,59)=4.00, p=0.024). Overall the Met/Met group performed worse than 
the Met/Val (t(44)=2.06, p=.045).  *p< 0.05. 
Figure 3. Mean and standard error of SRT Total Recall Split by Genotype and Index of Estrogen 
Exposure (ILEE) group. There was an interaction between COMT genotype and the ILEE groups 
for the total recall condition of the Buschke SRT for episodic memory (F(2,59)=3.67, p=0.03). 
Figure 4. Mean and standard error of Total SRT Recall Failure Split by Genotype and Index of 
Estrogen Exposure (ILEE) group. There was an interaction between COMT genotype and the 
ILEE for the total recall failure condition of the Buschke SRT for episodic memory 
(F(2,59)=7.22, p=0.002). For the Val/Val women, the low ILEE group had more recall failures, 
indicating worse performance, than the high ILEE group (t(17)=2.26, p=0.037). For the Met/Met 
group, the high estrogen exposure group had a greater amount of recall failures than the low 
estrogen group (t(8)=4.40, p=0.002). *p< 0.05. 
 
Figure 1.  
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